Background & Aims: Receptor tyrosine kinase (RTK) inhibitors have advanced colon cancer treatment.
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INTRODUCTION
Over a million cases of colon cancer are diagnosed annually worldwide 1 . Survival for advanced disease remains poor despite the use of recently-developed receptor tyrosine kinase (RTK) inhibitors such as regorafenib 2, 3 . Regorafenib's high-affinity targets include the VEGF receptor, EGFR, and the oncogenic kinases KIT, RET, and BRAF. Identifying which of these targets drives colon cancer progression would help identify patients for targeted therapy 4 . Because RTK inhibitors are nonspecific, genetic approaches are required for determining which RTKs are important for colon cancer growth.
KIT (CD117) is an RTK expressed in specialized goblet cells that contribute to the stem cell niche in the murine colon crypt base 5 . In human colon, KIT expression has been reported in several colon cancer cell lines, although KIT expression in primary colon tumors has been controversial [6] [7] [8] [9] [10] . KIT signaling occurs when it binds its only known ligand, KITLG (Stem Cell Factor), causing receptor dimerization, autophosphorylation, and intracellular signaling. KIT can promote cell growth, survival, migration, differentiation, and secretion in different biological contexts [11] [12] [13] . Activating/oncogenic mutations in KIT are well-documented in gastrointestinal stromal tumor (GIST), melanoma, and other diseases 11, 13 .
However, the roles of KIT and KITLG remain incompletely understood in colon cancer. Furthermore, studies on patient-derived xenografts are lacking.
Here we show that a subset of human colon cancers expresses KIT in the tumorigenic CD44+ fraction 14 .
Stable KIT knockdown inhibits colon cancer growth, increases expression of differentiation markers, and, unexpectedly, increases expression of stem cell-associated genes. KIT may drive tumor growth via autocrine and/or paracrine signaling by KITLG, since no activating KIT mutations were found.
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CD44+KIT+ cells are also highly tumorigenic. Our findings support the hypothesis that patients with KITexpressing colon tumors may benefit from KIT inhibition.
genome to minimize off-target effects . Five oligonucleotides each were screened for KIT and KITLG knockdown, and the best two were selected. A modified pSico-Pgk-GFP vector (plasmid# 12093, Addgene) containing the shRNA sequences preceded by the EF1α promoter, along with lentiviral packaging vectors Δ8.9 and VSVG, were transfected into 293T fibroblasts using FuGENE (Promega) 15 .
Flow Cytometry
Methods for flow cytometry have been previously described 5 . 
Single-cell Gene Expression Analysis
Double-sorted FACS-isolated single cells with purity > 95% were sorted into individual wells of 96-well plates containing 5 μL lysis buffer (Cells Direct qRT-PCR mix; Invitrogen) and 2U (0.1 μL) SuperaseIn (Invitrogen) and processed as described 5, 16 .
Bioluminescence Imaging
Colon cancer cells/xenografts engineered to constitutively express luciferase (LUC2) by lentiviral transduction were injected into flanks of NSG mice 17 . Mice received intraperitoneal injections of luciferin (Biosynth), and total flux (photons/second) was recorded.
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Immunofluorescence Imaging
Paraffin-embedded tissue sections were stained with mouse anti-human Ki67 (Clone MIB-1, Dako) and rabbit anti-human CD117 (cat# A4502, Dako) primary antibodies, with donkey anti-mouse Cy5 (cat# 715-175-150, Jackson ImmunoResearch) and goat anti-rabbit A568 (cat# SAB4600084, Sigma) secondary antibodies. Stained sections were mounted with ProLong Gold+Dapi (Molecular Probes).
Imatinib Experiments
Imatinib mesylate (LC Laboratories) was dissolved in phosphate buffered saline (PBS) at the specified concentrations for each experiment. For in vivo studies, imatinib 50 mg/kg/day or PBS control was administered to mice via intraperitoneal injections.
Statistical Analysis
Values represent mean, standard deviation, or standard error of mean as indicated. Differences between groups were determined using the two-tailed Student t-test. For Fig. 5A , one-way ANOVA was performed with Tukey's post-hoc test. For Fig. 6C , L-Calc (Stemcell Technologies) was used for limiting dilution analysis. All tests used a significance cutoff of p < 0.05. Analysis was performed with GraphPad Prism 5 (GraphPad Software Inc.).
RESULTS
Heterogeneous staining for KIT in a subset of human colon cancers
To assess KIT expression in colon cancer, we performed immunohistochemistry for KIT on a tumor microarray consisting of sections from 316 colon tumors: 137 primary tumors and 179 associated serially-passaged xenografts (Fig. 1A-C) . 36% of primary tumors and 51% of total tumors stained at least weakly for KIT (Fig. 1B) , in agreement with published proteomic data on colorectal cancer 9 . Some M A N U S C R I P T
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tumors showed scattered, strongly KIT-positive tumor cells, while others showed a diffuse staining pattern (Fig. 1C) . KIT staining was membrane-associated, cytoplasmic, or both. Flow cytometry analysis of several colon cancer cell lines and patient-derived xenografts also revealed variable KIT expression (Fig. 1D) . DLD1, LS174T, and COLO320DM cells are KIT hi , while HT29, SW620, CACO2, and HCT116 (not shown) are KIT lo/neg , agreeing with previous studies 18, 19 . UM-COLON#8 and POP77 are stable, moderately differentiated xenografts that express KIT in the tumorigenic CD44+ subpopulation 14 .
KIT+CD44-cells are also seen.
KIT knockdown inhibits growth of DLD1 in vitro and in vivo
To assess whether KIT promotes growth in colon cancer, we transduced DLD1, LS174T, and COLO320DM cells with two lentiviral shRNAs, shKit3 and shKit4 (Table S1 ). qRT-PCR, FACS, and Western blot confirmed strong KIT knockdown (Fig. S1 ). When grown in vitro, shKit3 and shKit4 cells exhibited decreased growth compared to vector control cells ( Fig. 2A) . DLD1, LS174T, and COLO320DM shKit cells also showed decreased EdU incorporation, indicating that fewer tumor cells entered S-phase upon KIT knockdown (Fig. 2B ). Phase contrast microscopy and FACS analysis showed that cell size, shape, and granularity were not significantly affected by KIT knockdown (data not shown).
Next, to assess the effect of KIT knockdown on growth in vivo, we injected DLD1 knockdown cells into one flank of immunocompromised mice and DLD1 control into the opposite flank. After 30 days of tumor growth, we observed an average tumor weight reduction of 62% with DLD1 shKit3 cells, and 79%
with shKit4 cells (Fig. 2C) . As a control, we knocked down KIT in the KIT lo/neg cell line HT29 and observed no significant change in tumor weight (Fig. 2C) . To measure the frequency of proliferative cells, we performed MKI67 staining on dissociated DLD1 shKit3 and shKit4 xenograft cells, and observed a 56%
and 41% decrease in MKI67 staining, respectively (Fig. 2D) . We confirmed that KIT remained stably M A N U S C R I P T
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knocked down in these tumors after their passage in vivo (Fig. S2) . Notably, hemotoxylin and eosin staining of DLD1 tumors showed that knockdown tumors exhibited less nuclear pleiomorphism and smaller, less prominent nucleoli (Fig. 2E )-pathologic features that correlate with less aggressive tumors. As expected, the average number of mitotic figures was smaller in knockdown DLD1 tumors (Fig. 2F) . These results show that KIT promotes growth in KIT+ colon cancers and that KIT lo/neg colon cancer cells are not dependent on KIT for growth.
Transcriptional changes upon KIT knockdown
We next assessed transcriptional changes occurring after KIT knockdown. We performed qRT-PCR and found that the enterocyte markers KRT20 and CEACAM1 were increased in DLD1 shKit3 and shKit4 tumors (Fig. 3A) , whereas no changes were seen with the goblet cell markers MUC2, SPINK4, and SPDEF (data not shown). Alcian blue staining of xenografts showed no goblet cells in knockdown or control tumors (data not shown). Thus, in addition to promoting colon cancer growth, KIT may inhibit expression of enterocyte differentiation markers.
Published reports from our group and others describing gene expression in normal murine and human colon-both in bulk and at the single-cell level-have identified genes that are enriched in LGR5+ cell populations. These "LGR5-associated genes" are putative stem/progenitor markers and include CD44, AXIN2, OLFM4, PTPRO, LRIG1, BMI1, ASCL2, and CFTR 5, 16, [20] [21] [22] . Notably, other studies have shown that genes enriched in LGR5+ intestinal stem cells may be highly expressed in aggressive colon cancers 21, 23 .
Unexpectedly, in DLD1 xenografts, we found a >50% increase in the expression of CD44 upon KIT knockdown (Fig. S3) . Levels of LGR5 itself and an LGR5-associated gene, AXIN2, remained unchanged (data not shown). Since the significance of stem-cell markers in cell lines is unclear, we investigated expression changes in LGR5-associated transcripts and other genes in xenografts. We knocked down KIT M A N U S C R I P T
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in the xenograft POP77 ( Fig. S4A ) and cultured organoids. Similar to DLD1 knockdowns, we saw increased expression of enterocyte markers KRT20, CEACAM1, and DPP4, and of the cyclin-dependent kinase inhibitor CDKN1A (Fig. 3B ), which marks non-proliferating cells. Interestingly, there was again an increase in the expression of LGR5 and an LGR5-associated gene, OLFM4, upon KIT knockdown (Fig. 3C ).
Our DLD1 and POP77 findings led us to perform single-cell qRT-PCR analysis on an additional xenograft, UM-COLON#8, to understand gene changes in greater detail. We characterized the tumorigenic CD44+
population from control and KIT knockdown UM-COLON#8 xenografts 14 . We confirmed KIT knockdown at both the RNA and protein level (Fig. 3D, S4B ), and performed unsupervised hierarchical clustering for genes of interest (Table S2 ) 16, 24 .
We found that, in the control tumor, CD44+KIT+ cells did not express high amounts of LGR5 and had generally lower levels of the LGR5-associated genes CD44, PTPRO, and LRIG1 ( Fig. 3D , blue box) 16 .
Conversely, in the knockdown tumor, we observed a cluster of KIT-cells expressing high levels of LGR5, CD44, PTPRO, LRIG1, and BMI1 ( Fig. 3D , purple box). This suggests that in UM-COLON#8, KIT and LGR5
are expressed in distinct subpopulations. As expected, the knockdown tumors also showed decreased expression of proliferation genes (MKI67, TOP2A, BIRC5), an increase in CDKN1A (Fig. 3D , E), and an increase in enterocyte markers (KRT20, DPP4, and CEACAM1). Together, our findings in DLD1, POP77, and UM-COLON#8 suggest that KIT promotes tumor growth in CD44+ cells while inhibiting the expression of enterocyte differentiation markers and LGR5-associated stem/progenitor-cell transcripts.
KIT signaling may occur in an autocrine or paracrine fashion in colon cancer
Pathogenic Kit signaling is implicated in several diseases (including GIST, leukemia, and melanoma),
where an activating mutation in exons 9, 11, 13, or 17-which encode the juxtamembrane and kinase domains of Kit-causes constitutive Kit-signaling 11, [25] [26] [27] . To assess whether KIT similarly promotes colon M A N U S C R I P T
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cancer growth via an activating mutation, we sequenced the aforementioned exons in DLD1, POP77, and UM-COLON#8 (Table S3 ) and found no mutations. This suggests that the trophic signal provided by KIT in colon cancer likely requires the presence of its ligand, KITLG.
To assess expression of KITLG in colon cancer, we performed immunohistochemistry for KITLG with our tumor microarray (Fig. 4A) . As with KIT, variable KITLG expression was observed, with 56% of primary tumors (and 57% of all tumor sections) exhibiting at least weak staining for KITLG (Fig. 4B ). KITLG immunoreactivity was detected in the tumor cells, tumor stroma, or both. Using qRT-PCR, we also found that several different colon cancer cell lines express KITLG (Fig. 4C ).
To determine whether KITLG-dependent signal transduction is responsible for KIT's growth-promoting activity, we knocked down KITLG in DLD1 using two independent shRNAs (Table S1 ). shKitlg1 and shKitlg2 reduced mRNA levels by >80% (Fig. S5 ). In vivo, DLD1 KITLG knockdown cells generated smaller xenografts compared to empty vector control cells (Fig. 4D ). We noted an average tumor weight reduction of 67% with DLD1 shKitlg1 cells, and 68% with DLD1 shKitlg2 cells (Fig. 4D) , similar to the reductions observed with shKit. These findings suggest that KIT promotes growth through KITLG expression in the tumor. Interestingly, we did not see a reliable increase in the expression of enterocyte markers or LGR-associated genes upon KITLG knockdown as we had with KIT knockdown (data not shown). This could be because KIT and KITLG knockdowns lead to quantitative differences in Kit signaling, which may have different effects on growth versus transcription of the genes we assayed.
Studies have shown that hypomorphic KIT alleles can have different phenotypes from KIT null alleles 28, 29 .
To assess for a potential autocrine or paracrine effect, we reviewed our single-cell analysis of UM-COLON#8 and observed many individual cancer cells that highly co-expressed KIT and KITLG, as well as M A N U S C R I P T
KIT+KITLG-and KIT-KITLG+ cells (Fig. 4E) . Additionally, our tumor arrays, which were stained as serial sections, showed that KITLG immunostaining can be seen in KIT+ tumor cells, in adjacent KIT-tumor cells, or in the stroma. In total, 35% of all primary tumors and xenografts, and 26% when counting primary tumors only, costained for KIT and KITLG (Fig. 4F ). This suggests that autocrine and paracrine KIT signaling may occur in tumors.
Imatinib inhibits growth of KIT+ colon cancers
We next asked whether imatinib, a clinically available RTK inhibitor with high-affinity for KIT, could inhibit the growth of KIT+ colon cancers. To test this in vitro, we dissociated POP77, a KIT+ xenograft that grows efficiently in vitro, to generate organoids. Treatment with imatinib at 10µM or higher decreased the size of POP77 organoids (Fig. 5A) , and led to the appearance of membranous blebs suggestive of cell death (Fig. 5B) . We found DLD1 to be inhibited by imatinib at similar concentrations, in agreement with previous studies (data not shown) 12 .
To determine whether imatinib can also inhibit growth in vivo, we injected DLD1 cells into the flanks of NSG mice and treated the mice with 50 mg/kg/day imatinib for 10 days. After treatment, mice receiving imatinib had smaller tumors than mice receiving the vehicle control (Fig. 5C ). We next treated luciferin-expressing UM-COLON#8 (UM-COLON#8-luc) tumors with imatinib for 14 days 17 . Using bioluminescent imaging, we found that imatinib-treated UM-COLON#8-luc tumors grew more slowly than untreated tumors even after discontinuation of imatinib (Fig. 5D ).
KIT expression enriches for tumorigenic colon cancer cells
Finally, given KIT's trophic role in colon cancer, we assessed whether KIT+ colon cancer cells may be more tumorigenic than their KIT-counterparts. We double-sorted DLD1 CD44+KIT+ and CD44+KIT-cells (>99% purity), and found that each gave rise to colonies containing KIT+ and KIT-subpopulations. FACS-M A N U S C R I P T
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sorted single KIT+ cells formed twice as many colonies as KIT-cells: 100 of 288 cells vs. 50 of 288 cells (Fig. 6A ). This suggests that KIT enriches for clonogenicity.
We next compared the in vivo tumorigenic potential of CD44+Kit+ and CD44+Kit-cells from the patientderived xenograft UM-COLON#8 by conducting limiting dilution experiments. Both CD44+KIT+ and CD44+KIT-cells could recapitulate the CD44 and KIT populations of the parental tumor (Fig. 6B ). In agreement with our DLD1 clonogenicity data, CD44+KIT+ cells were more tumorigenic than CD44+KIT-cells, with a tumorigenic frequency of 1:402 vs. 1:2415, respectively (Fig. 6C ).
Finally, we compared gene expression of CD44+KIT+ and CD44+KIT-cells at the single-cell level (Fig. 6D , Table S2 ). KITLG-expressing cells were found in both KIT+ and KIT-cells, again suggesting that KIT signaling may occur via autocrine/paracrine signaling. Additionally, the expression of several LGR5-associated transcripts was higher in the KIT-population, including LGR5, OLFM4, ASCL2, RNF43, CD44, and CFTR (Fig. 6D, E) . Meanwhile, the CD44+KIT+ cells possessed higher levels of enterocyte markers, including KRT20, CEACAM1, and CA2. KIT therefore marks a distinct population of tumorigenic colon cancer cells that exhibit unexpectedly lower levels of LGR5-associated stem/progenitor-cell transcripts.
Interestingly, single-cell gene expression of MKI67, TOP2A, and BIRC5 showed that both CD44+KIT+ and CD44+KIT-populations contain cycling cells. This was confirmed by MKI67 immunostaining in proliferating KIT+ cells (Fig. 6F) . To clarify the fraction of KIT+ and KIT-cells that are cycling, we conducted KIT and MKI67 co-immunostaining in sections of DLD1 and UM-COLON#8 xenografts (Fig. 7A) .
In both xenografts, we found that the MKI67+ (proliferative) cells were substantially more KIT+ than KIT- (Fig. 7B) . However, equivalent proportions of KIT+ and KIT-cells are MKI67+, suggesting that KIT signaling is not required for proliferation (Fig. 7C) .
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DISCUSSION
In this study, we used a colon cancer tumor microarray, cell lines, and patient-derived xenografts to
show that a significant fraction of human colon tumors express the receptor tyrosine kinase KIT and its ligand KITLG, and that the KIT/KITLG signaling axis may promote growth, particularly in the tumorigenic CD44+ fraction. Such tumors could be targeted by KIT receptor tyrosine kinase inhibitors like imatinib 30 .
By immunostaining a tumor microarray, we confirmed that KIT and KITLG are expressed by a subset of colon cancers, frequently in the same cells. Notably, our finding that 50% of tumors displayed at least low KIT immunoreactivity is higher than some reported findings 6, 10 , likely due to methodological differences (e.g., antigen retrieval, antibody used). However, our data are in line with a recently published proteogenomic analysis of a panel of human colorectal cancers, which showed that Kit is detected in 57 out of 95 samples 9 . Significantly, many tumors in our collection stained intensely for KIT in a subset of cells, reinforcing the idea that colon tumors exhibit heterogeneity of cell types that reflects normal developmental hierarchies 16 . Interestingly, we previously found using multivariate analysis of gene expression and outcomes in colon cancer that KIT expression does not predict clinical outcomes (data not shown). Furthermore, we remain uncertain why a subset of tumors expresses KIT, as KIT is not significantly amplified according to The Cancer Genome Atlas (data not shown). These are topics for further research. We observed that KIT knockdown decreases proliferation and also increases expression of several enterocyte differentiation markers. In development, cessation of proliferation frequently leads to a coincident increase in differentiation marker expression. In small intestinal crypts, for instance, undifferentiated proliferating stem and progenitor cells give rise to mature cell types that cease dividing as they mature. A similar inverse relationship between MKI67 (a proliferation marker) and KRT20 (a differentiation marker) has been observed in colon cancer. Our findings thus reinforce the idea that tumors maintain features of normal development 16 .
Currently, the precise interrelationship between various markers of stem cells in the colon crypt base is unclear 30 . This is even less well understood in non-homeostatic conditions such as injury or cancer, where non self-renewing progenitor populations may somehow acquire stem-cell features 35 .
Nevertheless, we observed that in cancer (as in normal murine colon) KIT-expressing cells are generally
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distinct from LGR5-expressing cells. Notably, CD44+KIT+ cells are highly tumorigenic even though they are relatively depleted for LGR5 and associated transcripts. This could be consistent with the finding that a non-LGR5 reserve stem cell population exists, and may be a secretory progenitor population 36, 37 , which could give rise to tumors. In addition, our tumorigenicity and gene expression data suggest that
LGR5-expression does not necessarily correlate with the aggressiveness of colon cancer, as others have suggested 23 . . In colon cancer, where KIT is not significantly mutated, it would seem unlikely that KIT inhibition would have a major effect since the tumors are likely to employ redundant pathways to promote their growth. In support of this, we have seen that relatively high concentrations of imatinib are required to block growth of KIT+ colon cancer organoids in vitro, as has a previous study 12 . However, in light of our in vivo data, KIT signaling in colon cancer may play an underappreciated growthstimulatory role, and could partially explain the beneficial effect of RTK inhibitors such as regorafenib.
Thus, screening colon tumors for KIT expression may help identify patients who would benefit from Kitinhibiting therapies.
In all, our findings support the use of Kit inhibitors for KIT+ colon cancers, and they highlight our need to better understand the role of receptor tyrosine kinases in colon cancer tumorigenesis. 
shRNA Lentiviral Transduction
shRNA oligonucleotides containing KIT-or KITLG-targeting sequences (Table S1) 
Flow Cytometry
Methods for flow cytometry have been previously described 3 . Briefly, cells in single-cell suspension were stained in the dark on ice with titered fluorescently-conjugated antibodies: Kit-PE (cat# 340529, BD Biosciences), Kit-PE-Cy7 (cat# 339195, BD Biosciences), CD44-PE-Cy7 (cat# M A N U S C R I P T
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with or without preceding preamplification with gene-specific primers) was conducted on an ABI7900HT Thermocycler using TaqMan assays (Applied Biosystems) for genes of interest (Table   S2 ). Samples were loaded in triplicate, and fold changes were calculated using ∆∆Ct, normalizing to glyceraldehyde-3-phosphate dehydrogenase or beta-actin.
Single-Cell Gene Expression
Double -sorted FACS-isolated single cells with purity > 95% were sorted into individual wells of 96-well plates containing 5 μL lysis buffer (CellsDirect qRT-PCR mix; Invitrogen) and 2 U (0.1 μL)
SuperaseIn (Invitrogen) and processed as described 3, 4 . For data analysis, single cell geneexpression results were normalized gene-by-gene, by mean-centering and dividing by 3 times the standard deviation of expressing cells. Unsupervised hierarchical clustering was performed on both cells and genes, with correlation distance metric and complete linkage 4 . P-values for differential gene expression were calculated using the Wilcoxon rank-sum test.
Bioluminescence Imaging
Colon cancer cells/xenografts engineered to constitutively express luciferase (LUC2) by lentiviral transduction were injected into the flanks of NSG mice 5 . To visualize bioluminescence, mice received intraperitoneal injections of luciferin (Biosynth), and were imaged on an IVIS Spectrum (Caliper Life Sciences) instrument and quantified using Living Image 4.0 Software (Caliper Life Sciences). Total flux (photons/second) was recorded for each tumor.
Immunofluorescence Imaging
As described previously 
Imatinib Experiments
Imatinib mesylate (LC Laboratories) was dissolved in phosphate buffered saline (PBS) at the specified concentrations for each experiment. For in vitro studies, dissolved imatinib was added to cell media, with PBS serving as the control. For in vivo studies, imatinib at a dose of 50 mg/kg/day was administered to mice via intraperitoneal injections.
Statistical Analysis
Values represent mean, standard deviation, or standard error of mean as indicated. Differences between groups were determined using the two-tailed Student t-test. For Fig. 5A , one-way ANOVA was performed with the Tukey's post-hoc test. For Fig. 5D , the dependent variable was transformed with the natural log and linear regression was performed. For Fig. 6C , L-Calc (Stemcell Technologies) was used for limiting dilution analysis. All tests were carried out with a significance cutoff of p < 0.05. Analysis was performed with GraphPad Prism 5.
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